FH Treatments and COVID-19

No Comments

As coronavirus virus disease 2019 (COVID-19) continues to spread in the United States and worldwide, the FH Foundation has received several questions related to the risk posed by COVID 19 for people with familial hypercholesterolemia (FH) and potential concerns about FH treatments at this time.

People with FH are not at increased risk of catching COVID-19 or of more severe illness due to COVID-19 simply by nature of having FH. However, people who have cardiovascular disease are at higher risk of more severe illness and even death due to COVID-19. This is a very important consideration for people who have FH, as many have established cardiovascular disease due to FH, and/or have family members who have established cardiovascular disease. It is very important that we all take precautions not to catch or spread COVID-19 by following CDC and other guidance. We can all do so much to protect ourselves, our families, and those who are more vulnerable.

The FH Foundation’s Chief Medical Officer, Dr. Mary McGowan, recently answered many of these questions in our COVID-19 and FH webinar. Following are a few of the most common questions. (Click on the title to expand the answer)

 

Questions?

Email the FH Foundation at info@thefhfoundation.org and we will respond to you. Sign up for our newsletters to keep informed of latest guidance related to FH and COVID-19.

 

References:
1. Repatha® (evolocumab) Prescribing Information
2. Toth PP, et al. Circulation. 2017;135(19):1819-1831.
3. Koren MJ, et al. J Am Coll Cardiol. 2019;74(17):2132-2146.
4. Sabatine MS, et al. N Engl J Med. 2017;376(18):1713-1722.
5. Amgen, Data on File
6. Praluent Safety Information for the U.S.

Leave a Reply